Please login to the form below

Not currently logged in
Email:
Password:

Sarepta

This page shows the latest Sarepta news and features for those working in and with pharma, biotech and healthcare.

Summit plunges after Duchenne disappointment

Summit plunges after Duchenne disappointment

Just last week Sarepta unveiled very early but promising data from a phase I/II clinical trial of a gene therapy which could eventually offer a cure. ... A wide range of other drug modalities are being explored by Sarepta and other companies, academics

Latest news

More from news
Approximately 7 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch February 2017 Deal Watch February 2017

    Licence. 145. Sarepta Therapeutics/ Gilead Sciences. PRV received when EXONDYS 51 was FDA approved for Duchenne muscular dystrophy.

  • Deal Watch October 2016 Deal Watch October 2016

    The licence deal obtained by Summit from Sarepta for a phase II product had an even lower upfront, 7% of the total consideration. ... 767. Sarepta (US). Summit (UK). Licence collaboration. Europe Utrophin modulator pipeline, lead molecule phase II for

  • Pharma deals during November 2014 Pharma deals during November 2014

    BioMarin clearly feels that there is still a real opportunity and is prepared to take on Sarepta and PTC Therapeutics in the competition to hustle ahead new DMD drugs to regulators.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Merrill Brink International

Merrill Brink International is a leading provider of life sciences, legal, financial, manufacturing and corporate language solutions for global companies....

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics